Every SEC Form 3/4/5 on record for this filer (CIK 1569926) — 6 issuers, 30 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| VTR | Ventas, Inc. | Director | 2019-07-26 → 2026-05-15 | 10 | $4,572 |
| TSHA | Taysha Gene Therapies, Inc. | Chief Executive Officer · Director | 2020-09-23 → 2026-01-27 | 13 | −$414,047 |
| DNAB | Social Capital Suvretta Holdings Corp. II | Director · lapsed | 2021-09-24 → 2021-09-24 | 1 | — |
| NLTX | Neoleukin Therapeutics, Inc. | Director · lapsed | 2019-10-15 → 2020-05-07 | 2 | — |
| AVXS | AveXis, Inc. | President & CEO · Director · lapsed | 2016-02-10 → 2018-05-15 | 6 | −$1M |
| AQXP | AQUINOX PHARMACEUTICALS, INC | Director · lapsed | 2016-05-11 → 2018-05-09 | 3 | — |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| TSHA | 2026-01-26 | Sell | 41,312 | $4.61 | $190,448 | 2,908,257 |
| TSHA | 2026-01-23 | Sell | 136,789 | $4.75 | $649,748 | 2,949,569 |
| TSHA | 2023-08-16 | Buy | 444,444 | $0.90 | $400,000 | 1,535,545 |
2 of 6 issuers are covered and open a security page; the rest are on file here only.
